Where the claims come from

Liraglutide is not a grey-market compound and is not controversial. It is on this site as a comparison: it is the drug semaglutide and tirzepatide largely replaced, and its trial record shows what a fully developed peptide medicine looks like — hundreds of registered trials, published outcomes, and approvals tied to specific populations.

What evidence exists outside the registry

Nearly four hundred registered interventional trials, plus an extensive published literature including cardiovascular outcome studies. Much of its recent registry presence is as the active comparator in trials of newer drugs, which is itself a sign of a mature evidence base.

Sources for this section

Victoza FDA label — Approved for glycaemic control in type 2 diabetes, patients 10 and older, and cardiovascular risk reduction.
Saxenda FDA label — Approved for chronic weight management, with specific age and weight criteria.

Approved for, studied for, sold for

Three separate lists, kept by three separate processes: a regulator decides the first, researchers the second, and whoever is selling it the third. They are often not the same list, and the differences are the most useful thing on this page.

Approved for

US Food and Drug Administration

FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications.

Studied for

ClinicalTrials.gov · interventional, human

Diabetes
Diabetes Mellitus, Type 2
Obesity
Type 2 Diabetes
Type 2 Diabetes Mellitus
Healthy
Type 1 Diabetes
Metabolism and Nutrition Disorder

Marketed for

Claims made by sellers

Weight loss
Blood sugar control

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Weight loss

Studied Blood sugar control

Every trial on record

Every registered human study we can find for Liraglutide. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT05681299	Effects of GH and Lirglutide on AgRP	Healthy, Growth Hormone Deficiency	Phase 4	Recruiting now	40
NCT06865365	Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone	Obesity, Adolescent	Phase 4	Not yet recruiting	72
NCT06836284	The Evira Study: Additional Support During Obesity Treatment	Childhood Obesity, Treatment Adherence	Not phased	Recruiting now	40
NCT07244003	Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control	T2DM (Type 2 Diabetes Mellitus)	Phase 4	Recruiting now	430
NCT06976619	The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes	Type 1 Diabetes, Type 2 Diabetes	Phase 2	Recruiting now	60
NCT07301437	RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.	Overweight and Obese Adults	Phase 4	Not yet recruiting	120
NCT06742710	Liraglutide Treatment in Obese Infertile PCOS Women	PCOS, Obesity	Phase 4	Recruiting now	890
NCT03087032	Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)	Type 2 Diabetes Patients, Overweight and Obesity	Phase 4	Recruiting now	164
NCT07029009	Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)	Maturity Onset Diabetes of the Young	Phase 2	Recruiting now	50
NCT05268237	Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus	Diabete Type 2	Phase 2	Recruiting now	15
NCT06559722	A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes	Type 2 Diabetes	Phase 3	Not yet recruiting	510
NCT04575844	Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome	Metabolic Syndrome	Phase 4	Recruiting now	80
NCT07225816	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)	Obesity	Phase 1	Recruiting now	71
NCT06361238	Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery	Delirium, Postoperative	Phase 3	Recruiting now	260
NCT02100475	A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	31
NCT02298192	A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	420
NCT00983021	Safety and Tolerability of NN9068 in Healthy Male Volunteers	Diabetes, Healthy	Phase 1	Completed	24
NCT01511185	Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	20
NCT01722266	Liraglutide in the Treatment of Type 1 Diabetes Mellitus	Type 1 Diabetes	Phase 3	Completed	72
NCT01800968	Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)	Acute Heart Failure	Phase 2	Completed	300
NCT01319240	Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects	Diabetes, Healthy	Phase 1	Completed	24
NCT01499108	Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes	Type 2 Diabetes	Phase 4	Completed	32
NCT02351232	The Lira Pump Trial	Type 1 Diabetes	Phase 3	Completed	44
NCT01856790	Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes	Type 1 Diabetes	Phase 1	Completed	15
NCT00518882	Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	467
NCT03191396	Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	577
NCT00781937	Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	422
NCT01761318	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients	Diabetes Mellitus Type 2, Metabolic Syndrome	Phase 4	Completed	50
NCT02905864	Liraglutide 3 mg for Knee Osteoarthritis	Osteoarthritis, Obesity	Phase 4	Completed	150
NCT01388361	Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	413
NCT01508806	Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	30
NCT05294536	A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects	Type 2 Diabetes	Phase 1	Completed	50
NCT00154401	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	177
NCT01785043	Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users	DIABETES Mellitus Type 2 Not Well Controlled	Phase 4	Completed	13
NCT01664247	The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	346
NCT01508923	Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	17
NCT01779362	RISE Adult Medication Study	Prediabetes, Type 2 Diabetes	Phase 3	Completed	267
NCT01392573	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	413
NCT01336023	Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	1663
NCT04190160	Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)	Type2 Diabetes	Not phased	Completed	35
NCT01744236	SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies	Type 2 Diabetes	Phase 4	Completed	70
NCT01536665	The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes	Diabetes, Diabetes Mellitus, Type 1	Phase 1	Completed	45
NCT01836523	The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes	Diabetes, Diabetes Mellitus, Type 1	Phase 3	Completed	1398
NCT02787551	Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period	Type 2 Diabetes Mellitus	Phase 3	Completed	514
NCT02501161	A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	1012
NCT03041792	Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects	Obesity	Phase 1	Completed	61
NCT01722240	Liraglutide in Type 1 Diabetes	Type 1 Diabetes	Phase 3	Completed	69
NCT02060383	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Cushing's Disease, Acromegaly	Phase 4	Completed	249
NCT03260881	Liraglutide Effects on Epicardial Fat Inflammatory Genes	Type2 Diabetes, Coronary Artery Disease	Phase 4	Completed	38
NCT03712098	Daily Liraglutide for Nicotine Dependence	Smoking Cessation, Weight, Body	Phase 2	Completed	40
NCT01620463	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	32
NCT01739049	Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese	Binge Eating Behaviour	Phase 4	Completed	42
NCT03347890	Reward Mechanisms in Obesity	Obesity	Phase 4	Completed	70
NCT00318461	To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	1091
NCT06400615	Study That Tests AD109 in Patients Taking GLP-1 Drugs	OSA	Phase 2	Completed	40
NCT01518166	Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH	Diabetes, Healthy	Phase 1	Completed	70
NCT02963922	Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	396
NCT02765399	The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis	Type 2 Diabetes	Phase 4	Completed	23
NCT02043054	Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)	Type 2 Diabetes Mellitus, Cardiovascular Disease	Phase 3	Completed	90
NCT06818292	Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists	Healthy	Not phased	Completed	10
NCT01794143	A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes	Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications	Phase 3	Completed	7850
NCT05579249	A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America	Obesity	Phase 4	Completed	500
NCT03856047	Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.	Overweight, Obesity	Phase 2	Completed	706
NCT01664676	Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients	Type 2 Diabetes Mellitus	Phase 4	Completed	11
NCT05313529	LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes	Type 2 Diabetes Mellitus, Mild Cognitive Impairment	Not phased	Completed	396
NCT02686177	Effect of GLP-1 on Angiogenesis	Type 2 Diabetes	Phase 4	Completed	50
NCT02527200	Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	56
NCT02207348	Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	24
NCT01654120	Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics	Diabetes Mellitus, Type II	Phase 4	Completed	37
NCT00395746	Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	264
NCT02964247	LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	303
NCT01425580	Liraglutide and Heart Failure in Type 2 Diabetes	Congestive Heart Failure, Type 2 Diabetes Mellitus	Phase 2	Completed	62
NCT02910570	Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis	Osteoarthritis, Knee	Phase 4	Completed	150
NCT06500130	Effects of Liraglutide on Body Surface Gastric Mapping	Gastroparesis, Functional Dyspepsia	Not phased	Completed	22
NCT02717858	A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	52
NCT01617434	The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	451
NCT03466021	Effects of Liraglutide in Chronic Obstructive Pulmonary Disease	Pulmonary Disease, Chronic Obstructive	Phase 4	Completed	40
NCT03374956	Individualized Obesity Pharmacotherapy	Obesity	Phase 3	Completed	193
NCT01272232	Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	846
NCT01179048	Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	9341
NCT03523273	Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity	Obesity	Phase 2	Completed	136
NCT01610934	The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)	Maturity-onset Diabetes of the Young	Phase 3	Completed	15
NCT05390307	Obesity Treatment to Improve Diabetes	Type 1 Diabetes	Not phased	Completed	60
NCT02453711	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus	Metabolism and Nutrition Disorder, Obesity	Phase 2	Completed	957
NCT01472640	The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus	Hyperglycemia, Chronic Heart Failure	Not phased	Completed	240
NCT02931383	Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance	Osteoarthritis, Obesity	Phase 4	Completed	150
NCT01512108	Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	363
NCT01832532	A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks	Sleep Apnea, Sleep Disordered Breathing	Phase 2	Completed	34
NCT00993304	A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	20
NCT01795248	The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes	Gestational Diabetes Mellitus	Phase 4	Completed	105
NCT01562678	Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI	Diabetes, Effects of Liraglutide Administration on Brain Activity	Phase 4	Completed	28
NCT01917656	Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 4	Completed	343
NCT01513525	Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers	Diabetes, Healthy	Phase 1	Completed	21
NCT00873223	Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	33
NCT03175120	A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	453
NCT01516255	Effect of Liraglutide on Heart Frequency in Healthy Volunteers	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	64
NCT02205528	A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Diabetes, Diabetes Mellitus Type 2	Phase 2	Completed	108
NCT05794581	A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes	Type 1 Diabetes	Phase 1	Completed	32
NCT01558271	A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Phase 3	Completed	492
NCT02617654	Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes	Type 1 Diabetes	Phase 2	Completed	18
NCT01208012	Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus	Diabetes Mellitus, Type 2	Phase 4	Completed	44
NCT00700817	The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	665
NCT02324842	Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients	Type 2 Diabetes Mellitus	Not phased	Completed	45
NCT00761540	To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo	Diabetes, Healthy	Phase 1	Completed	37
NCT01557166	Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	359
NCT02773368	A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	420
NCT03862716	Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira	Type 2 Diabetes Mellitus	Phase 3	Completed	159
NCT02518945	Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes	Type 1 Diabetes Mellitus	Phase 3	Completed	26
NCT03795701	To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity	Obesity	Not phased	Completed	73
NCT03642600	The Gut Microbiome in Women With Polycystic Ovary Syndrome	PCOS, Obesity	Phase 4	Completed	21
NCT02696148	A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	24
NCT02647944	Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity	Obesity	Phase 2	Completed	40
NCT03449654	Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes	Diabetes Mellitus, Type 2	Phase 4	Completed	102
NCT01782261	Incretin Effect on the Immunological Phenotype	Type 1 Diabetes	Phase 2	Completed	15
NCT02602600	Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis	Microvascular Angina	Phase 4	Completed	33
NCT02870231	Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	187
NCT01517568	Metabolism and Excretion of Liraglutide in Healthy Male Volunteers	Diabetes, Healthy	Phase 1	Completed	7
NCT00993720	Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes	Diabetes Mellitus	Phase 3	Completed	30
NCT00856986	The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	987
NCT01620489	Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	279
NCT01966978	The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study	Diabetes Mellitus, Type 2, Diabetes	Phase 4	Completed	157
NCT05360537	Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients	Diabetes Mellitus, Type 2	Phase 4	Completed	100
NCT02516657	Liraglutide in Adolescents With Type 1 Diabetes	Type 1 Diabetes	Phase 3	Completed	5
NCT03034941	Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients	Obesity, PCOS	Phase 4	Completed	35
NCT02908087	Incretin-based Therapy in Early Diagnosed Type 1 Diabetes	Type 1 Diabetes	Phase 2	Completed	13
NCT01270789	LIraglutide and Beta-cell RepAir (LIBRA) Study	Type 2 Diabetes	Phase 3	Completed	63
NCT01620476	Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers	Diabetes, Healthy	Phase 1	Completed	24
NCT04199728	Use of a GLP-1R Agonist to Treat Opioid Use Disorder	Opiate Substitution Treatment, Opioid-Related Disorders	Phase 2	Completed	27
NCT01596504	Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin	Type 2 Diabetes Mellitus	Phase 2	Completed	142
NCT02057172	Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes	Type 2 Diabetes	Phase 2	Completed	254
NCT05225974	A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects	Therapeutic Equivalency	Phase 1	Completed	32
NCT06201819	Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery	Weight Loss, Bariatric Surgery Candidate	Phase 4	Completed	37
NCT02650206	Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood	Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II	Phase 1	Completed	56
NCT01515553	Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers	Diabetes, Healthy	Phase 1	Completed	22
NCT01879917	Liraglutide in Newly Onset Type 1 Diabetes.	Diabetes Mellitus, Type 1	Phase 3	Completed	65
NCT02299388	To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study	Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease	Phase 4	Completed	11
NCT02889510	Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus	Type 2 Diabetes	Phase 3	Completed	76
NCT01272219	Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	3731
NCT04311411	A Study of Tirzepatide in Overweight and Very Overweight Participants	Obesity, Overweight	Phase 1	Completed	114
NCT01507272	Safety and Tolerability of Liraglutide in Healthy Male Volunteers	Diabetes, Healthy	Phase 1	Completed	34
NCT03172494	A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	720
NCT00943501	Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	21
NCT03353948	The Effect of a Liraglutide on IVF in Obese PCOS	Polycystic Ovary Syndrome, Obesity	Phase 4	Completed	30
NCT01128894	A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.	Diabetes Mellitus, Type 2	Phase 3	Completed	841
NCT04605861	The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients	Obese, Overweight	Phase 3	Completed	414
NCT01507285	Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	24
NCT02909933	Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity	Polycystic Ovary Syndrome, Obesity	Phase 4	Completed	30
NCT03036800	Saxenda in Obesity Services (STRIVE Study)	Obesity, Weight Loss	Phase 4	Completed	392
NCT04903509	A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide	Healthy	Phase 1	Completed	95
NCT01363609	Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes	Obesity, Type 2 Diabetes	Not phased	Completed	50
NCT02292290	Trial for People With Established Type 2 Diabetes During Ramadan	Type 2 Diabetes	Phase 4	Completed	99
NCT01237119	Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis	Nonalcoholic Steatohepatitis	Phase 2	Completed	52
NCT02082496	GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations	Obesity	Phase 2	Completed	50
NCT02545738	Antiproteinuric Effects of Liraglutide Treatment	Diabetic Kidney Disease	Phase 4	Completed	32
NCT01509755	Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	196
NCT03480022	Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS	Pre Diabetes, Polycystic Ovary Syndrome	Phase 3	Completed	88
NCT01460069	The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis	Psoriasis	Not phased	Completed	20
NCT01787916	52 Week Trial of Liraglutide in Type 1 Diabetes	Type 1 Diabetes	Phase 4	Completed	15
NCT02073929	LIPT - Liraglutide in Polycystic Ovary Syndrome	Polycystic Ovary Syndrome, Cardiovascular Disease	Phase 4	Completed	72
NCT03068065	Antidiabetic Effects on Intrahepatic Fat	Non-Alcoholic Fatty Liver Disease, Type2 Diabetes	Phase 4	Completed	87
NCT01870297	A Study of LY3025876 in Participants With Diabetes	Type 2 Diabetes Mellitus	Phase 1	Completed	72
NCT01755416	Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting	Type 1 Diabetes	Phase 2	Completed	18
NCT04781998	Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?	Mental Disorder, Metabolic Disturbance	Phase 4	Completed	24
NCT01740921	GLP-1 and Microvascular Function in Type 2 Diabetes	Type 2 Diabetes	Not phased	Completed	39
NCT01117350	Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure	Diabetes Mellitus, Type 2	Phase 4	Completed	978
NCT03158805	Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)	Bipolar Disorder, Obesity	Phase 2	Completed	60
NCT01755572	Blood Pressure Outcomes With Liraglutide Therapy	Type 2 Diabetes, Systolic Hypertension	Phase 4	Completed	22
NCT01517555	Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	18
NCT02638805	Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide	Diabetes Mellitus, Type 2	Phase 3	Completed	136
NCT02832999	Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes	Type 2 Diabetes Mellitus	Phase 4	Completed	14
NCT02488057	Improving Beta Cell Function in Mexican American Women With Prediabetes	Pre-Diabetes	Phase 4	Completed	360
NCT01595789	The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes	Coronary Artery Disease, Diabetes Mellitus, Type 2	Phase 4	Completed	41
NCT02973321	A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Phase 2	Completed	296
NCT02138045	Treatment of Diabetic Neuropathy With Liraglutide	Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus	Not phased	Completed	39
NCT05419856	Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee	Knee Osteoarthritis	Phase 1	Completed	34
NCT03341429	Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response	Obesity	Phase 4	Completed	70
NCT05467514	Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus	Diabetes Mellitus, Type 1	Phase 3	Completed	35
NCT01511692	Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	43
NCT00154414	Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	226
NCT01455441	The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes	Type 2 Diabetes	Phase 4	Completed	40
NCT02092896	Liraglutide as add-on to Insulin in Type 1 Diabetes	Diabetes, Diabetes Mellitus, Type 1	Phase 3	Completed	40
NCT02008682	The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 4	Completed	368
NCT04883346	Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy	Obesity, Status Post Sleeve Gastrectomy	Phase 2	Completed	34
NCT03292185	A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	24
NCT01514487	Comparison of Three Liraglutide Formulations in Healthy Volunteers	Diabetes, Healthy	Phase 1	Completed	24
NCT01029886	Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes	Type 2 Diabetes Mellitus	Phase 3	Completed	912
NCT01952145	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	557
NCT03010683	Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus	Type 2 Diabetes Mellitus, Coronary Artery Disease	Not phased	Completed	60
NCT01518101	Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications	Type 2 Diabetes	Phase 4	Completed	62
NCT03115424	Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy	Obesity	Phase 3	Completed	46
NCT06439056	Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D	Type 2 Diabetes	Phase 1	Completed	12
NCT07374445	Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery	Obesity, Weight Loss	Phase 4	Completed	100
NCT04325581	Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients	Weight Loss	Phase 3	Completed	16
NCT02928679	Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance	Osteoarthritis, Obesity	Phase 4	Completed	150
NCT01296412	Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)	Diabetes Mellitus, Type 2	Phase 3	Completed	653
NCT00696657	A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	415
NCT02730377	Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 4	Completed	1991
NCT02104037	Liraglutide in Spinal Fluid	Liraglutide Blood-brain Transfer	Not phased	Completed	8
NCT02918279	Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	251
NCT06533527	Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy	Diabetes Mellitus, Type 2, Obesity	Phase 4	Completed	69
NCT01695109	The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers	Healthy Human Male Subjects	Phase 4	Completed	16
NCT01982630	Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)	Diabetes Mellitus	Phase 1	Completed	87
NCT02963935	Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting	Metabolism and Nutrition Disorder, Obesity	Phase 3	Completed	282
NCT02777073	Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes	Type 1 Diabetes	Not phased	Completed	43
NCT02863419	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	711
NCT01907854	Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin	Diabetes, Diabetes Mellitus, Type 2	Phase 4	Completed	407
NCT00393718	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	400
NCT02911948	A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	210
NCT01658501	Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM	Type 2 Diabetes Mellitus	Phase 2	Completed	593
NCT01515579	Comparison of Two Liraglutide Formulations in Healthy Subjects	Diabetes, Healthy	Phase 1	Completed	22
NCT03038620	Impact of Liraglutide 3.0 on Body Fat Distribution	Obesity, Visceral, Cardiovascular Diseases	Phase 4	Completed	235
NCT03707171	Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Phase 3	Completed	30
NCT01687582	Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients	Type 2 Diabetes, Psoriasis	Not phased	Completed	10
NCT02041234	Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment	Type II Diabetes in Subjects BMI 27 to 32	Phase 4	Completed	40
NCT03672812	The Use of Liraglutide in Brain Death	Brain Death	Phase 3	Completed	50
NCT02960659	Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes	Type 2 Diabetes	Phase 2	Completed	24
NCT01725126	To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes	Obesity	Phase 2	Completed	53
NCT05965908	Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome	Polycystic Ovary	Phase 3	Completed	150
NCT03486392	A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants	Obesity	Phase 2	Completed	474
NCT01508858	Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	21
NCT01615978	Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	15
NCT01234649	Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)	Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus	Phase 3	Completed	153
NCT02616003	Preoperative Condition in Giant Obese Patients	Morbid Obesity, Bariatric Surgery Candidate	Phase 4	Completed	50
NCT03619330	Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.	Hypogonadism, Obesity	Phase 4	Completed	30
NCT04074161	Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity	Overweight, Obesity	Phase 3	Completed	338
NCT01624259	A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes	Type 2 Diabetes	Phase 3	Completed	599
NCT03632759	Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D	Type 1 Diabetes Mellitus	Phase 1	Completed	16
NCT02403284	The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans	Insulin Resistance	Phase 4	Completed	97
NCT01919489	Liraglutide Hospital Discharge Trial	Type 2 Diabetes	Phase 4	Completed	273
NCT03757130	Multiple Ascending Dose Study of AMG 598 in Adults With Obesity	Obesity	Phase 1	Completed	50
NCT01509742	Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	19
NCT03955575	Treatment of Bile Acid Malabsorption With Liraglutide	Bile Acid Malabsorption	Phase 4	Completed	52
NCT01911468	Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin	PCOS, Obesity	Phase 4	Completed	36
NCT02187250	PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome	PCOS, Obesity	Phase 4	Completed	45
NCT01515592	Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	24
NCT03048578	Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery	Obesity	Phase 4	Completed	132
NCT03235050	A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes	Diabetes Mellitus, Type 2	Phase 2	Completed	834
NCT01507389	Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	24
NCT05360147	Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus	Type 2 Diabetes Mellitus	Phase 3	Completed	30
NCT01550653	Liraglutide Effects on Memory in Healthy Subjects	Healthy	Phase 1	Completed	40
NCT02443155	A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function	Diabetes, Diabetes Mellitus, Type 1	Phase 2	Completed	308
NCT03555994	A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.	Type 2 Diabetes Mellitus	Phase 2	Completed	51
NCT05444569	A Study of LY3537021 in Healthy Participants	Healthy	Phase 1	Completed	47
NCT01916174	A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	50
NCT03534310	Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg	Obesity	Not phased	Completed	75
NCT03018028	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	243
NCT00620282	The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	49
NCT03520062	The Effect of Liraglutide on Pancreatic Hormones and Its Size	Obesity	Not phased	Completed	14
NCT02473809	The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function	Diabetes Complications, Osteoporosis	Phase 4	Completed	60
NCT01508897	Comparison of Two Liraglutide Formulations in Healthy Volunteers	Diabetes, Healthy	Phase 1	Completed	22
NCT01232946	Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake	Type 2 Diabetes	Not phased	Completed	30
NCT01373450	Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)	Type 2 Diabetes Mellitus	Phase 1	Completed	12
NCT04186494	Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea	Sleep Apnea, Obstructive	Not phased	Completed	30
NCT02953665	Safety and Efficacy of Liraglutide in Parkinson's Disease	Parkinson Disease	Phase 2	Completed	63
NCT02898506	Incretin-based Therapy in Late Preclinical Type 1 Diabetes	Type 1 Diabetes	Phase 2	Completed	13
NCT00333151	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	576
NCT01175473	Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes	Type 2 Diabetes Mellitus	Phase 2	Completed	148
NCT01973231	Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 4	Completed	404
NCT01618162	The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	435
NCT05111912	Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity	Obesity	Phase 2	Completed	206
NCT02505334	A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	635
NCT02147925	Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects	Non-alcoholic Fatty Liver Disease	Phase 4	Completed	75
NCT01541215	Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	135
NCT02098395	The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes	Diabetes, Diabetes Mellitus, Type 1	Phase 3	Completed	835
NCT01511198	Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	223
NCT02089256	Effect of Repeated Administration of Liraglutide on Insulinogenic Indices	Healthy	Phase 4	Completed	10
NCT02423824	Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists	Bipolar Disorder, Major Depressive Disorder	Phase 3	Completed	21
NCT01847313	The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease	Diabetic Kidney Disease	Phase 3	Completed	20
NCT01511159	Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers	Diabetes, Healthy	Phase 1	Completed	32
NCT01789086	A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	21
NCT00331851	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	584
NCT01676116	The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	438
NCT02036372	Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus	Diabetes Mellitus Type II	Not phased	Completed	150
NCT02607306	A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	819
NCT01473953	Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	31
NCT01784965	Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.	Pre-diabetes, Older Adults	Phase 3	Completed	69
NCT02483299	Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome	PCOS, Obesity	Phase 4	Completed	40
NCT01507337	Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers	Diabetes, Healthy	Phase 1	Completed	32
NCT02928614	Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance	Osteoarthritis, Obesity	Phase 4	Completed	150
NCT01505673	Adding Liraglutide to High Dose Insulin: Breaking the Cycle	Type 2 Diabetes Mellitus, Obesity	Phase 4	Completed	71
NCT00422058	The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes	Metabolism and Nutrition Disorder, Obesity	Phase 2	Completed	564
NCT01733758	A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)	Diabetes Mellitus, Type 2	Phase 3	Completed	494
NCT01753362	Liraglutide In Overweight Patients With Type 1 Diabetes	Type 1 Diabetes	Phase 3	Completed	84
NCT02408705	Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects	Type 1 Diabetes Mellitus	Phase 2	Completed	14
NCT03115099	A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes	Diabetes Mellitus, Type 2	Phase 1	Completed	80
NCT02655770	Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients	Diabetes Mellitus Type 2, Diastolic Dysfunction	Phase 4	Completed	40
NCT01572740	Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	257
NCT04881110	Liraglutide and Peripheral Artery Disease	Type 2 Diabetes, Peripheral Arterial Disease	Phase 4	Completed	60
NCT01575301	DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists	Diabetes	Not phased	Completed	411
NCT01931982	Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.	Type 2 Diabetes, Microvascular Dysfunction	Phase 4	Completed	20
NCT01511172	Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	145
NCT02420262	A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	506
NCT03101930	Cardiovascular Effects of GLP-1 Receptor Activation	Obesity, PreDiabetes	Phase 4	Completed	329
NCT01937598	Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D	Type 2 Diabetes	Phase 3	Completed	16
NCT01599338	Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients	Type 2 Diabetes Mellitus, Overweight	Not phased	Completed	30
NCT00978393	A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	49
NCT02014740	Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes	Type 2 Diabetes, Overweight	Phase 4	Completed	100
NCT02235961	Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects	Metabolism and Nutrition Disorder, Obesity	Phase 1	Completed	163
NCT01677104	The Microvascular Function of GLP-1 and Its Analogues	Type 2 Diabetes, Obesity	Not phased	Completed	63
NCT04829903	Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin	Type 2 Diabetes Treated With Insulin, Obesity	Not phased	Completed	116
NCT03737240	IDegLira HIGH Trial	Diabetes Mellitus	Phase 3	Completed	145
NCT01399645	Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes	Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis	Phase 2	Completed	35
NCT02140983	Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes	Insulin Resistance, Dementia	Phase 1	Completed	41
NCT01394341	Liraglutide Treatment to Patients With Severe Renal Insufficiency	Type 2 Diabetes Mellitus, End-stage Renal Disease	Phase 4	Completed	40
NCT02461589	Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	706
NCT03182426	Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)	Diabetes Mellitus, Type 1	Phase 2	Completed	22
NCT00318422	Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	1041
NCT01507311	Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 1	Completed	11
NCT03151005	The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS	Polycystic Ovary Syndrome (PCOS), Overweight	Phase 4	Completed	70
NCT02911818	Lifestyle Modification and Liraglutide	Obesity	Phase 4	Completed	150
NCT02315001	Liraglutide to Improve corONary Haemodynamics During Exercise streSS	Ischaemic Heart Disease, Coronary Heart Disease	Phase 2	Completed	26
NCT02113332	Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections	Type 2 Diabetes Mellitus	Phase 2	Completed	124
NCT05029076	Human Bioequivalence Test of Liraglutide Injection	Type 2 Diabetes	Phase 1	Completed	28
NCT01469351	Identifying Potential Effects of Liraglutide on Degenerative Changes	Alzheimers Disease	Not phased	Completed	34
NCT02527993	Treatment of Hypoglycemia Following Gastric Bypass Surgery	Hypoglycemia, Obesity	Phase 4	Completed	11
NCT00614120	Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Completed	929
NCT01612468	Liraglutide in Type 1 Diabetes	Diabetes Mellitus, Type 1, Overweight	Phase 4	Completed	100
NCT02660047	Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent	Diabetes Mellitus Type 2, Metabolic Syndrome	Phase 4	Completed	51
NCT01508949	Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes	Diabetes, Diabetes Mellitus, Type 2	Phase 2	Completed	35
NCT04657939	Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes	Diabetes Mellitus, Type 2	Phase 4	Completed	57
NCT01899430	Polycystic Ovary Syndrome and Liraglutide	PCOS, Obesity	Phase 4	Completed	32
NCT01592279	GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients	Uncontrolled Type 1 Diabetic Patients	Phase 4	Status not updated	124
NCT05767255	Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue	Diabetes Mellitus, Type 2 Treated With Insulin	Phase 3	Status not updated	66
NCT04324229	Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes	Gestational Diabetes	Not phased	Running, closed to new participants	80
NCT07590219	Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity	Severe Obesity, Cardiovascular Function	Phase 4	Running, closed to new participants	30
NCT03500484	Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.	Obesity, Childhood, Neural Development	Phase 1	Stopped early	13
NCT02584582	The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate	Type 1 Diabetes	Phase 3	Status not updated	10
NCT07325435	Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists	Type 2 Diabetes (T2DM)	Phase 4	Running, closed to new participants	60
NCT04839237	The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients	Obesity	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT02674893	Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes	Type 2 Diabetes, Overweight	Phase 4	Stopped early	48
NCT01451905	GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis	Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI	Not phased	Status not updated	12
NCT02417103	Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid	Obesity	Phase 3	Stopped early	2
NCT05705388	POSE2.0 With GLP-1 Agonist for Obesity Management	Obesity	Not phased	Status not updated	50
NCT01593137	A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes	Type 2 Diabetes	Phase 4	Withdrawn before enrolling	0 — nobody enrolled
NCT06925334	A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus	Type 2 Diabetic Patients	Phase 4	ENROLLING_BY_INVITATION	170
NCT02721888	Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism	Type 2 Diabetes	Phase 4	Stopped early	127
NCT06449703	A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects	Healthy	Phase 1	Status not updated	44
NCT02535299	Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment	GLP-1；Metformin；Telomere-telomerase System；Par-4	Phase 4	Status not updated	200
NCT04057261	Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease	Type 2 Diabetes, Cardiovascular Diseases	Phase 3	Withdrawn before enrolling	0 — nobody enrolled
NCT04046822	Effect of Liraglutide on Microbiome in Obesity	Obesity, Weight Loss	Phase 4	Status not updated	70
NCT02001363	Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury	Acute Myocardial Infarction	Not phased	Status not updated	90
NCT04531176	EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial	Type 2 Diabetes, Obesity	Phase 4	Stopped early	74
NCT02650596	Effects of GLP-1 on Chronic Heart Failure	Heart Failure	Not phased	Status not updated	68
NCT02072096	A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)	Diabetes Mellitus, Type 2	Phase 4	Stopped early	192
NCT02284230	The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure	Kidney Failure, Chronic, Prediabetic State	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT02507128	Effects of Glucagon Like Peptide-1 on No-reflow	Acute ST-segment Elevation Myocardial Infarction	Not phased	Status not updated	190
NCT03426085	The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes	Autonomic Nervous System Diseases, Sweat Gland Diseases	Phase 2	Status not updated	44
NCT06408532	The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes	Diabetes Mellitus, Type 2	Phase 4	Status not updated	256
NCT02490176	Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters	Heart Failure	Not phased	Status not updated	50
NCT03948347	Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus	Ischemic Stroke, Transient Ischemic Attack	Not phased	Status not updated	1708
NCT01954147	Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus	Type 2 Diabetes	Phase 2	Status not updated	100
NCT06438146	LIROH - Liraglutide for Obesity in HIV	Obesity, HIV Infections	Phase 4	Status not updated	40
NCT02344186	Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	Type 2 Diabetes	Phase 4	Status not updated	12
NCT05952882	Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility	Polycystic Ovary Syndrome, Obesity	Phase 3	Status not updated	188
NCT05268627	Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss	Obesity	Not phased	Status not updated	38
NCT06171152	Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues	Multiple Sclerosis, Long COVID	Phase 1	Suspended	30
NCT01845259	Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?	Impaired Glucose Tolerance Associated With Drugs	Phase 2	Status not updated	103
NCT05285397	Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.	Morbid Obesity	Not phased	Status not updated	60
NCT02718950	Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans	Obesity, Type 2 Diabetes Mellitus	Phase 3	Status not updated	20
NCT04146155	Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease	Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus	Phase 4	Status not updated	200
NCT04122716	Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet	Obesity	Phase 4	Status not updated	215
NCT02231658	Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion	Diabetes Mellitus	Phase 1	Stopped early	109
NCT04525300	Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities	Obesity	Phase 3	Status not updated	300
NCT03883412	Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)	Type2 Diabetes	Phase 4	Status not updated	60
NCT02244164	Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.	Type 2 Diabetes, Incretinomimetics	Not phased	Stopped early	5
NCT02472717	Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study	Psoriatic Arthritis, Psoriasis	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT01638260	GLP-1 and Non-exercise Activity Thermogenesis in RHZ	Type 2 Diabetes Mellitus	Phase 4	Stopped early	22
NCT05779644	Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus	Metformin, Obesity, Abdominal	Not phased	Status not updated	300
NCT03371862	Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)	Short Bowel Syndrome	Phase 2	Withdrawn before enrolling	0 — nobody enrolled
NCT01206101	Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation	Diabetes, Diabetes Mellitus, Type 1	Phase 2	Stopped early	3
NCT03011021	Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes	Type1 Diabetes Mellitus, Autoimmune Diabetes	Phase 2	Status not updated	40
NCT04643301	Liraglutide for Low-responders After Bariatric Surgery	Obesity, Obesity, Morbid	Not phased	Withdrawn before enrolling	0 — nobody enrolled
NCT06217848	The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study	Panhypopituitarism, Craniopharyngioma	Phase 1	Status not updated	50
NCT02783196	Effect of Liraglutide on Clock Genes	Type 2 Diabetes	Not phased	Status not updated	14
NCT02611232	Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults	Type 1 Diabetes	Phase 2	Status not updated	42
NCT04683237	Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia	Atypical Endometrial Hyperplasia, Obese	Phase 3	Withdrawn before enrolling	0 — nobody enrolled
NCT01628445	Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin	Type 2 Diabetes	Phase 3	Stopped early	52
NCT02109315	Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.	Type 1 Diabetes Mellitus	Phase 1	Withdrawn before enrolling	0 — nobody enrolled
NCT04775082	SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity	Obesity	Phase 3	Running, closed to new participants	78
NCT04373967	Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes	Type 2 Diabetes	Phase 3	Status not updated	424
NCT04487743	Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities	Obesity	Phase 3	Status not updated	300
NCT01934816	Incretin and KATP Channels	Healthy Subjects	Not phased	Stopped early	2
NCT06501326	Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease	Non-alcoholic Fatty Liver Disease, Obesity	Phase 4	Status not updated	102
NCT04529278	Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients	Diabetes Mellitus, Type 2, Hemodialysis	Phase 2	Status not updated	18
NCT04535960	Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial	Type 2 Diabetes Mellitus	Phase 2	Status not updated	36
NCT02055014	Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)	Type 2 Diabetes, Obesity	Phase 4	Status not updated	72
NCT01722227	Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes	Type 1 Diabetes	Phase 3	Withdrawn before enrolling	0 — nobody enrolled
NCT02577848	GLP-1 on Non-ST-Segment Elevation Myocardial Infarction	Myocardial Infarction	Not phased	Status not updated	90
NCT04008290	The Effect of Liraglutide on the GIT	Obesity	Phase 4	Status not updated	15
NCT01790308	Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function	Diabetes Mellitus, Type 2	Phase 4	Status not updated	100
NCT04575194	Study of the Cardiometabolic Effects of Obesity Pharmacotherapy	Obesity, Blood Pressure	Phase 4	Status not updated	40
NCT02198209	Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation	Type 2 Diabetes	Phase 4	Withdrawn before enrolling	0 — nobody enrolled
NCT04137328	Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide	Diabetic Neuropathic Pain	Not phased	Status not updated	60
NCT02503943	Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes	Type 2 Diabetes, Overweight	Phase 4	Status not updated	90
NCT02920190	Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat	Monoclonal Gammopathies, Overweight	Phase 4	Withdrawn before enrolling	0 — nobody enrolled
NCT07225829	A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis	Knee Osteoarthritis, Synovitis of Knee	Phase 2	Running, closed to new participants	129
NCT01392898	Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes	Type 2 Diabetes Mellitus	Not phased	Status not updated	50
NCT02654665	Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults	Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss	Phase 3	Status not updated	36
NCT03671733	Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients	Obesity	Phase 3	Status not updated	150
NCT03011008	Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus	Type 1 Diabetes Mellitus, Autoimmune Diabetes	Phase 4	Status not updated	20
NCT00294723	To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c	Diabetes, Diabetes Mellitus, Type 2	Phase 3	Stopped early	746
NCT03279731	Binge Eating Liraglutide Intervention	Binge-Eating Disorder	Phase 3	Stopped early	36
NCT01843075	Evaluating Liraglutide in Alzheimer's Disease	Alzheimer's Disease	Phase 2	Status not updated	204
NCT02501850	The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	Diabetes Mellitus Type 2	Phase 4	Status not updated	40
NCT02743598	Liraglutide for HIV-associated Neurocognitive Disorder	HIV Infection, Diabetes Mellitus Type 2	Phase 4	Stopped early	4
NCT02930265	Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy	Ischemic Cardiomyopathy	Not phased	Status not updated	400
NCT03421119	Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes	Diabetes Mellitus, Type 2	Phase 3	Status not updated	300
NCT02944500	Saxenda: Underlying Mechanisms and Clinical Outcomes	Obesity	Phase 4	Running, closed to new participants	28
NCT04763564	Efficacy of Liraglutide Therapy in Patients With IPAA	Pouchitis, Irritable Pouch Syndrome	Phase 2	Stopped early	8
NCT02016846	Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes	Glucocorticoid Induced Hyperglycemia	Phase 3	Status not updated	36
NCT01542242	Liraglutide Use in Prader-Willi Syndrome	Diabetes Mellitus Type 2, Prader Willi Syndrome	Phase 4	Stopped early	1
NCT03986008	Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients	Obesity	Phase 3	Status not updated	60
NCT01516476	Study of RO6807952 in Patients With Diabetes Mellitus Type 2	Diabetes Mellitus Type 2	Phase 2	Stopped early	2
NCT02492763	A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)	Type II Diabetes Mellitus	Phase 2	Stopped early	176
NCT03856632	Liraglutide Effect in Atrial Fibrillation	Atrial Fibrillation	Phase 4	Running, closed to new participants	60
NCT05041673	Anti-diabetic Drugs and Fatty Liver Management	Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2	Not phased	Status not updated	120
NCT02059564	A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus	Diabetes Mellitus	Phase 1	Status not updated	44
NCT01597531	Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding	Type 2 Diabetes, Gastric Banding	Phase 4	Stopped early	1
NCT02879409	HbA1c Variability in Type II Diabetes	Diabetes Mellitus Type 2	Not phased	Running, closed to new participants	150

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

What regulators have said

We searched FDA's list of bulk drug substances nominated for use in pharmacy compounding and did not find Liraglutide on it, in any category. That means there is no published FDA safety assessment to report — not that the compound has been reviewed and cleared.

FDA — bulk drug substances that may present significant safety risks

Checked against FDA's published list on 2026-07-30. This list changes; the link goes to the current version.

Why sources disagree on this number

Different sites publish different counts for Liraglutide because they are answering different questions. Here is every way of counting the same set of studies, so you can see which rule produces which number.

419

Registered human trials the number we publish

Interventional studies in people, listed on ClinicalTrials.gov, at any status.

307

Completed

Registered trials whose status is "completed".

Still running

Recruiting, not yet recruiting, or active.

Stopped early

Terminated, withdrawn, or suspended.

371

With a stated phase

Registered trials tagged Phase 1-4.

155

100+ participants

Registered trials enrolling at least 100 people.

Observational studies

Studies that watch rather than intervene.

You may see a lower number than 419.

Sources that count only completed studies get 307. We count registered trials at any status, because a trial that is recruiting is still a real trial and is the thing most likely to change this page. Neither number is wrong; they answer different questions.

Some counts only include trials with a stated phase.

That yields 371 rather than 419. Not every registered study is tagged with a phase — some are marked "not applicable" — so phase-only counts run lower.

Which number should you use?

For "how much human evidence exists", 419 is the honest answer, with the caveat that 307 have actually finished. Every trial is listed on this page with its ID — if you disagree with how we count, you can recount it yourself in about a minute.

Common questions about Liraglutide

How many human trials does Liraglutide have?

419. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Liraglutide FDA approved?

Yes, but read the detail: FDA-approved as Victoza for type 2 diabetes in patients 10 and older, and as Saxenda for chronic weight management. Two products, two separate indications. An approval for one condition is not an approval for everything it is marketed for.

What is Liraglutide actually being tested for?

Registered studies cover: healthy, growth hormone deficiency, obesity, adolescent. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.

More on Liraglutide: how many human trials it has · is it FDA approved · has it been studied for safety · what it is studied for